

Chul Ha, M.D.
NOTE : If you're an existing patient, please connect via MyChart
-
About Me
About Chul Ha, M.D.
Chul S. Ha, MD, is professor and chair emeritus of the Department of Radiation Oncology at the Mays Cancer Center, home to UT Health San Antonio MD Anderson. He is a nationally recognized expert in radiation oncology, especially for hematological malignancies such as lymphoma, myeloma and leukemia. He has a special expertise in unique treatment procedures such as total body irradiation in preparation for bone marrow transplant, total skin electron beam radiation therapy for certain skin malignancies and radioimmunotherapy for lymphomas. His current research interest includes the development of drugs that reduce the side effects of DNA damaging agents such as radiation and chemotherapy. He graduated summa cum laude from Rice University with a bachelor’s degree in biochemistry. He obtained his MD from Harvard Medical School and completed residency training at Harvard Joint Center for Radiation Therapy. He spent 14 years at the University of Texas M.D. Anderson Cancer Center before joining the faculty at University of Texas Health Science Center San Antonio.
Gender
- Male
Languages Spoken
- English
- Korean
Chul Ha | Radiation Oncology
Trust should be at the core of any personal relationship including physician and patient.
-
Credentials
Credentials
Positions
- Professor, University of Texas Health Science Center San Antonio
Certifications
- American Board of Radiology/Radiation Oncology
Education
- Medical School: Harvard Medical School, Boston, MA
- Internship: Harvard Medical School, Boston, MA
- Residency: Harvard Medical School, Boston, MA
-
Locations & Contact
Locations & Contact
Dr Ha was very courteous, understanding, very friendly and explained everything and answered my questions very thoroughly, and in a way I could understand. He was patient & showed compassion. His staff was also very friendly, helpful, & understanding.
Patient
-
Research & Publications
Research & Publications
Low-dose arsenic induces chemotherapy protection via p53/NF-kappaB-mediated metabolic regulation
Ganapathy, S., Xiao, S., Seo, S. J., Lall, R., Yang, M., Xu, T., Su, H., Shadfan, M., Ha, C. S. & Yuan, Z. M.
Oncogene doi: 10.1038/onc.2013.81(2013). PMID: 23524579
p53-Based Strategy for Protection of Bone Marrow From Y-90 Ibritumomab Tiuxetan
Su, H., Ganapathy, S., Li, X., Yuan, Z. M. & Ha, C. S.
Int. J. Radiat. Oncol. Biol. Phys. 1;92(5):1116-22 (2015). PMID: 26025778; PMCID: PMC4509863
Tolerance of Phellodendron amurense Bark Extract (Nexrutine(R)) in Patients with Human Prostate Cancer
Swanson, G. P., Jones, W. E.,3rd, Ha, C. S., Jenkins, C. A., Kumar, A. P. & Basler, J.
Phytother. Res. 29(1):40-2 (2014). PMID: 25205619; PMCID: PMC4507270
- Clinical Trials